You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
盘中异动 | 药明生物盘中上涨5%,报于66.7港元
uSMART盈立智投 09-12 09:30

2022年9月9日16时0分,药明生物(HK02269)盘中上涨5%,报于66.7港元,成交额达9.97亿港元,换手率达到0.36%。

8月30日讯,数字医疗完善医改“中国方案” 微医入选福布斯2022中国创新力企业50强。

8月22日,里昂:维持药明生物(02269)“跑赢大市”评级,目标价升至84港元。8月19日,瑞银:重申药明生物(02269)“买入”评级,目标价升至113.12港元。8月19日,招银国际:维持药明生物(02269)“买入”评级,目标价120.39港元。

最新的财务数据显示,公司于2022年1季度,营业收入36.03亿人民币,净利润13.11亿人民币;营业收入同比增加63.53%,毛利润同比增加49.08%,净利润同比增加39.22%。

盈立趋势长盈模型最近一次交易信号,2022年9月9日出现关注信号,触发价格为66.7港元(信号仅供参考)。

uSMART智能写手的信息、数据均来自媒体公开报道,智能写手不能保证其完全准确,内容仅供参考,不构成投资建议。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account